At a glance
ClinicalIndex Comparison RecordPhase 1Unknown· 24 target
Drug / intervention
Surufatinib/humanized anti-PD-1 monoclonal antibodydrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase I Trial Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Surufatinib Combined With JS001 in Patients With Advanced Solid Tumors
In Brief
A Phase 1 clinical trial evaluating Surufatinib/humanized anti-PD-1 monoclonal antibody for Solid Tumor. Targeting 24 participants across 1 site.
Detailed Summary
This is an open-label, phase I study evaluating safety, tolerability, pharmacokinetics and efficacy of Surufatinib combined with the humanized anti-PD-1 antibody JS001 in patients with solid tumors.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSolid Tumor
CountriesChina
Collaborators--
Timeline
Phase 1UnknownOverdue
20192020202120222023202420252026
Enrollment StartDec 2018
First PostedMar 2019
Primary CompletionDec 2020
Study CompletionDec 2021
TodayJul 2026
First PostedMar 18, 2019
Enrollment StartDec 21, 2018
Primary CompletionDec 20, 2020
Study CompletionDec 20, 2021
TodayJul 1, 2026
Enrollment to primary: 2.0 yearsPosted 7.3 years ago
Interventions
Surufatinib/humanized anti-PD-1 monoclonal antibodydrug
humanized anti-PD-1 monoclonal antibody(JS001) is a programmed death-1 (PD-1) immune checkpoint inhibitor antibody, which selectively interferes with th combination of PD-1 with its ligands, PD-L1 and PD-L2, resulting in the activitation of lymphocytes and elimination of malignancy theoretically.